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INTRODUCTION
Thyroid cancer is the most common cancer between ages 15 
years and 64 years, and the most common cancer in women in 
Korea (1). The incidence of thyroid cancer has increased during 
the past 15-20 years, particularly for papillary thyroid cancer 
(PTC), which is the predominant subtype of malignant thyroid 
cancers (2, 3). Ionizing radiation exposure, diet, smoking, and 
hormonal factors are the risk factors for thyroid cancer (4, 5). 
Genetic predisposition has been implicated as a risk factor for 
PTC (6, 7). Case-control studies based on large populations have 
demonstrated that the genetic risk of thyroid cancer is about three 
to eight fold higher than that of any other major cancer (8, 9).
  Apoptosis is involved in the destructive action of autoimmune 
thyroid disorders and in cell death of thyroid cancer. Apoptosis, 
programmed cell death, plays a crucial role in the prevention of 
uncontrolled cell growth and cancerous cells have developed 
mechanisms to avoid apoptosis. B-cell CLL/lymphoma 2 (BCL2) 
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is known to protect cells from apoptosis and is firstly found in 
the BCL2 family. Members of BCL2 family can be classified into 
anti-apoptotic and pro-apoptotic proteins. Anti-apoptotic BCL2 
family members are BCL2, BCL2-like 1 (BCL2L1, transcript 
BCLXL), BCL2L2, and myeloid cell leukemia sequence 1 
(BCL2-related) (MCL1, transcript MCL1L). Pro-apoptotic BCL2 
family members are divided into two types according to BCL2 
homolog (BH) domains (BH1-4). Major pro-apoptotic BCL2 
family members containing only BH3 domain are BCL2-associ-
ated agonist of cell death (BAD), BH3 interacting domain death 
agonist (BID), BCL2-like 11 (apoptosis facilitator) (BCL2L11), 
Bcl2 modifying factor (BMF), and MCL1 (transcript MCL1S). 
Minor members containing other domains include BCL2-associ-
ated X protein (BAX), BCL2-related ovarian killer (BOK), 
BCL2-antagonist/killer 1 (BAK1), and BCL2L1 (transcript 
BCLXS) (10, 11). The BCL family has an important role in the 
pathogenesis of thyroid cancer (12-14). In PTC, the apoptotic 
index correlates inversely with BCL2 expression (13). BCL2 ex-
pression is associated with differentiation of thyroid cancer (12), 
but a study found no relationship between BCL2 expression and 
the thyroid cancer differentiation (14). The role of BCL2 on the 
development and clinicopathologic features of thyroid cancer is 
largely unknown. Single nucleotide polymorphisms (SNPs) of 
BCL2 have been studied in several cancers, including chronic 
lymphocytic leukemia (15, 16), prostate cancer (17), ovarian 
cancer (18), breast cancer (19), renal cancer (20), oropharyngeal 
squamous cell carcinoma (21), and sporadic medullary thyroid 
carcinoma (22). To date, no study has investigated for association 
between BCL2 SNPs and PTC. The aim of this study was to in-
vestigate whether promoter SNP (rs2279115, -938A/C) and 
synonymous SNP (rs1801018, Thr7Thr) in the BCL2 gene were 
associated with PTC development in the Korean population. We 
also investigated for relationships between BCL2 SNPs and clin-
iopathologic features, such as size, number (unifocality and mul-
tifocality), location (one lobe and both lobe), extrathyroid inva-
sion, and lymph node metastasis.
MATERIALS AND METHODS
Patients and controls 
PTC patients were enrolled at the Kyung Hee University Medi-
cal Center, Seoul, Korea between October 2007 and December 
2010. Control subjects were selected from healthy individuals 
examined under a general health check-up program without 
clinical evidence of cancers, thyroid diseases, or any other se-
vere conditions. PTC and the cervical regional lymph node me-
tastasis were confirmed by pathologic examination. Specimens 
confirmed as benign tumor, follicular variant, diffuse sclerosing 
and tall cell variants were excluded. Fifteen patients of 170 were 
excluded. The patient group (n=92) was comprised of 26 males 
and 66 females. The mean age of the patients was 53.5±12.0 
years (mean±standard deviation [SD]). The control group was 
consisted of 222 healthy adults (53.8±6.0 years), comprised of 
94 males and 128 females. This study was approved by the eth-
ics review board of the Medical Research Institute, Kyung Hee 
University Medical Center (KMC IRB 1010-05). Written in-
formed consent was obtained from each subject prior to study 
entry. 
Patient subgroups 
To determine the nature of the relationship between BCL2 SNPs 
and the clinicopathologic characteristics of PTC, patients were 
divided into subgroups according to tumor size (<1 cm and ≥1 
cm), number of tumors (unifocality and multifocality), location 
of cancer (one lobe and both lobe), extrathyroid invasion (pres-
ence and absence), angiolymphatic invasion (presence and ab-
sence) and cervical lymph node metastasis (presence and ab-
sence). Demographic characteristics of PTC patients are summa-
rized in Table 1; small differences in subgroup numbers were 
caused by loss of clinical data.
SNP selection and genotyping 
We searched the promoter and coding SNPs of the BCL2 gene 
in the SNP database of the National Center for Biotechnology 
Information (http://www.ncbi.nlm.nih.gov/SNP, BUILD 132). 
SNPs with unknown heterozygosity, minor allele frequency 
(MAF) below 10%, and unknown genotype in Asians were ex-
cluded. Out of 7 SNPs in the promoter region, there were 3 SNPs 
with no heterozygosity data, 1 SNP with heterozygosity below 
0.05, and 2 SNPs with unknown genotype in Asians. Among 5 
coding SNPs, 3 SNPs with heterozygosity were below 0.05 and 
1 SNP was with unknown MAF. Finally, two SNPs (rs2279115, 
-938A/C; rs1801018, Thr7Thr) were selected. These SNPs were 
also cited in several studies. Blood samples for DNA extraction 
from each subject were collected in EDTA tube and then stored 
in a -80℃ refrigerator. Genomic DNA was extracted using a 
QIAamp
® DNA mini kit (QIAGEN, Valencia, CA, USA). SNP 
genotyping was determined by direct sequencing. Polymerase 
chain reactions (PCRs) were performed using specific primers 
Table 1. Clinical characteristics of the enrolled 92 patients with papil-
lary thyroid carcinoma (PTC) 
Characteristics Values
Age (years, mean±SD)  53.5±12.0
Sex (male:female) 26:66
Cancer size ≥ 1 cm 47 (52)
Multifocality 30 (34)
Both lobe 26 (29)
Extrathyroidal invasion  47 (53)
Cervical lymph node metastasis 25 (29)
Angiolymphatic invasion 5 (6)
Values are presented as number (%). Numbers are different, because PTC 
patients with inappropriate clinical data were excluded.
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for BCL2 SNPs that were selected for analysis: for rs2279115 
(sense, 5′-ATAAAACCCTCCCCCACCACCT-3′; antisense, 5′- 
ACAATTTTCAGTCCGGTATTCG-3′; product size, 343 bp) 
and for rs1801018 (sense, 5′- GGGGAAACACCAGAAT-
CAAGT-3′; antisense, 5′- GGGCTGGGAGGAGAAGATGC-3′; 
product size, 334 bp). The PCR products were sequenced using 
an ABI PRISM 3730XL analyzer (PE Applied Biosystems, Foster 
City, CA, USA). Sequencing data were analyzed using SeqMa-
nII software (DNASTAR, Madison, WI, USA).
Statistical analysis 
Continuous variables are presented as mean±SD using the in-
dependent t-test and chi square test. Hardy–Weinberg equilibri-
um (HWE) was calculated using the SNPStats software (http://
bioinfo.iconcologia.net/index.php?module=Snpstats) in both 
patient and control groups. SPSS ver. 18.0 (SPSS Inc., Chicago, 
IL, USA) program and SNPStats were used to analyze genetic 
data. Linkage disequilibrium (LD) block and haplotypes were 
evaluated using Haploview version 4.2 (23). Multiple logistic re-
gression models adjusted for gender and sex (codominant1, co-
dominant2, dominant, recessive, overdominant, and log-additive) 
were employed to obtain odds ratios (ORs), 95% confidence in-
tervals (CIs), and P-values. Fisher exact test and Bonferroni cor-
rection were also performed. Statistical significance was set at 
P<0.05.
RESULTS
Genotypic distributions of the two SNPs examined in this study 
were in HWE (P>0.05, data not shown). Genetic associations 
between BCL2 and PTC were investigated. Multiple logistic re-
gression analysis was performed: for the promoter SNP 
rs2279115, -938A/C (codominant 1, C/C vs. A/C; codominant 
2, C/C vs. A/A; dominant, C/C vs. A/C + A/A; recessive, C/C + 
A/C vs. A/A; overdominant, C/C + A/A vs. A/C; log-additive, C/
C vs. A/C vs. A/A) and for the synonymous SNP rs1801018, 
Thr7Thr (codominant 1, A/A vs. A/G; codominant 2, A/A vs. G/
G; dominant, A/A vs. A/G + G/G; recessive, A/A + A/G vs. G/G; 
overdominant, A/A + G/G vs. A/G; log-additive, A/A vs. A/G vs. 
G/G). 
  In analyses of genotype data from 92 PTC patients and 222 
controls, the frequencies of BCL2 SNP (rs1801018, Thr7Thr) 
were different in PTC and control (dominant model [A/A+A/G 
vs. G/G]: OR, 0.51; 95% CI, 0.26 to 1.00; P=0.042; overdomi-
nant model [G/G vs. A/A]: OR, 0.49; 95% CI, 0.25 to 0.99; P=
0.036). However, the association disappeared after performing 
Bonferroni correction. The BCL2 promoter SNP (rs2279115, 
-938A/C) was not associated with PTC (Table 2).
  One LD block by the Gabriel method was made (24). LD 
block was consisted of rs2279115 and rs1801018 of BCL2, and 
3 haplotypes were constructed (Fig. 1). In haplotype analysis, 
haplotypes were not associated with PTC (Table 3).
  When we assessed the genetic relationships between SNPs and 
subgroups of PTC patients, BCL2 SNP (rs1801018) was signifi-
cantly associated with PTC multifocality (P=0.036 in genotype 
frequency after Bonferroni correction; P=0.046 in allele fre-
quency after Bonferroni correction) and bilaterality (P=0.008 in 
genotype frequency after Bonferroni correction; P=0.012 in al-
lele frequency after Bonferroni correction) (Tables 4 and 5). The 
Table 2. Genotype and allele frequencies of SNPs of BCL2 gene in PTC and control subjects 
SNP Type
Control PTC
Model OR (95% CI) P-value
Fisher exact 
P-value
Bonferroni 
correction  
P-value No. (%)
rs2279115 Genotype C/C 80 (36.0) 40 (43.5) Codominant1 0.64 (0.38-1.10) 0.15  0.30 
-938 A/C A/C 109 (49.1) 37 (40.2) Codominant2 0.89 (0.43-1.85) 0.80  1.00 
A/A 33 (14.9) 15 (16.3) Dominant 0.70 (0.42-1.16) 0.17  0.34 
Recessive 1.13 (0.58-2.21) 0.73  1.00 
Overdominant 0.67 (0.40-1.10) 0.11  0.22 
Log-additive 0.87 (0.61-1.24) 0.43  0.86 
Allele C 269 (60.6) 117 (63.6) 1
A 175 (39.4) 67 (36.4) 0.88 (0.62-1.26) 0.48  0.96 
rs1801018 Genotype A/A 170 (76.6) 79 (85.9) Codominant1 0.49 (0.25-0.98) 0.07  0.14 
Thr7Thr A/G 49 (22.1) 12 (13.0) Codominant2 0.93 (0.09-9.35) 0.76  1.00 
G/G 3 (1.4) 1 (1.1) Dominant 0.51 (0.26-1.00) 0.042   0.08 
Recessive 1.02 (0.10-10.30) 0.98  1.00  1.00 
Overdominant 0.49 (0.25-0.99) 0.036   0.07 
Log-additive 0.56 (0.30-1.05) 0.06  0.12 
Allele A 389 (87.6) 170 (92.4) 1
G 55 (12.4) 14 (7.6) 0.58 (0.32-1.08) 0.08  0.16 
The P-values were calculated from logistic regression analyses adjusting sex and age. Bold numbers mean significance association.
SNP: singe nucleotide polymorphism; BCL2: B-cell CLL/lymphoma 2; PTC: papillary thyroid cancer; OR: odds ratio; CI: confidence interval.152    Clinical and Experimental Otorhinolaryngology   Vol. 4, No. 3: 149-154, September 2011
G allele frequencies of rs1801018 in PTC patients with multifo-
cality (13.3%) were about four-fold higher than those in PTC 
patients with unifocality (3.4%). The G allele frequencies of 
rs1801018 in PTC patients with both lobes (15.4%) were in-
Table 3. Haplotype analysis of BLC2 polymorphisms in PTC and 
control subjects
Haplotype Frequency
Control PTC Chi  
square
P-value
+ - + -
CA 0.615 269 175 117 67 0.50 0.48
AA 0.275 120 324 53 131 0.21 0.65
AG 0.11 55 389 14 170 3.04 0.08
Haplotype is comprised of rs2279115 and rs1801018.
BCL2: B-cell CLL/lymphoma 2; PTC: papillary thyroid cancer. 
Table 4. Genotype and allele frequencies of SNPs of BCL2 gene in PTC patients with unifocality and PTC patients with multifocality
SNP Type
Unifocality Multifocality
Model OR (95% CI) P-value
Fisher exact
P-value
Bonferroni
correction P-value No. (%)
rs2279115 Genotype C/C 24 (40.7) 14 (46.7) Codominant1 0.77 (0.29-2.05) 0.69  1.00 
-938 A/C A/C 25 (42.4) 12 (40.0) Codominant2 0.62 (0.16-2.43) 0.58  1.00 
A/A 10 (16.9) 4 (13.3) Dominant 0.73 (0.30-1.81) 0.50  1.00 
Recessive 0.71 (0.20-2.53) 0.59  0.77 1.00 
Overdominant 0.88 (0.36-2.17) 0.78  1.00 
Log-additive 0.79 (0.41-1.49) 0.46  0.96 
Allele A 45 (38.1) 20 (33.3) 1
C 73 (61.9) 40 (66.7) 1.23 (0.64-2.37) 0.53 1.00 
rs1801018 Genotype A/A 55 (93.2) 22 (73.3) 1
Thr7Thr A/G 4 (6.8) 8 (26.7) 5.00 (1.37-18.31) 0.015 0.018 0.036
G/G 0 (0.0) 0 (0.0)
Allele A 114 (96.6) 52 (86.7) 1
G 4 (3.4) 8 (13.3) 4.39 (1.26-15.22) 0.020  0.023 0.046
The P-values were calculated from logistic regression analyses adjusting sex and age. Bold numbers mean significance association.
SNP: singe nucleotide polymorphism; BCL2: B-cell CLL/lymphoma 2; PTC: papillary thyroid cancer; OR: odds ratio; CI: confidence interval.
Table 5. Genotype and allele frequencies of SNPs of BCL2 gene in PTC patients with one lobe and PTC patients with both lobe
SNP Type
One lobe Both lobe
Model OR (95% CI) P-value
Fisher exact 
P-value
Bonferroni
correction P-value No. (%)
rs2279115 Genotype C/C 28 (44.4) 10 (38.5) Codominant1 1.10 (0.39-3.14) 0.56  1.00 
-938 A/C A/C 25 (39.7) 12 (46.1) Codominant2 0.81 (0.19-3.38) 0.87  1.00 
A/A 10 (15.9) 4 (15.4) Dominant 1.01 (0.38-2.71) 0.98  1.00 
Recessive 0.77 (0.21-2.85) 0.69  1.00  1.00 
Overdominant 1.17 (0.45-3.06) 0.75  1.00 
Log-additive 0.94 (0.48-1.84) 0.85  1.00 
Allele C 45 (35.7) 20 (38.5) 1
A 81 (64.3) 32 (61.5) 0.89 (0.46-1.73) 0.73 1.00 
rs1801018 Genotype A/A 59 (93.7) 18 (69.2) 1
Thr7Thr A/G 4 (6.3) 8 (30.8) 6.56 (1.77-24.32) 0.005 0.004 0.008
G/G 0 (0.0) 0 (0.0)
Allele A 122 (96.8) 44 (84.6) 1
G 4 (3.2) 8 (15.4) 5.55 (1.59-19.33) 0.007 0.006 0.012
The P-values were calculated from logistic regression analyses adjusting sex and age. Bold numbers mean significance association.
SNP: singe nucleotide polymorphism; BCL2: B-cell CLL/lymphoma 2; PTC: papillary thyroid cancer; OR: odds ratio; CI: confidence interval.
Fig. 1. Linkage disequilibrium block consists of rs2279115 and 
rs1801018.
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creased by about five-fold compared to PTC patients with one 
cancerous lobe (3.2%). However, BCL2 SNPs (rs2279115 and 
rs1801018) were not associated with size, extrathyroid invasion, 
angiolymphatic invasion or lymph node metastasis.
DISCUSSION
This is the first study to investigate the association between 
BCL2 SNPs and PTC in the Korean population. We analyzed 
the promoter SNP (rs2279115, -938A/C) and synonymous SNP 
(rs1801018, Thr7Thr) in PTC patients and control subjects. We 
also assessed the relationships between two SNPs (rs2279115, 
-938A/C; rs1801018, Thr7Thr) and the clinicopathologic char-
acteristics of PTC. Our results showed that synonymous SNP 
(rs1801018, Thr7Thr) of the BCL2 was weakly associated with 
the development of PTC (P=0.042 in dominant model, P=0.082 
after Bonferroni correction; P=0.036 in dominant model, P=
0.072 after Bonferroni correction). Haplotype was not different 
between PTC patients and control subjects. Regarding the clini-
copathologic features of PTC, the synonymous rs1801018 SNP 
was associated with the number (unifocality and multifocality) 
(P=0.018 in genotype frequency adjusting Fisher exact test, 
P=0.036 after Bonferroni correction; P=0.023 in allele frequen-
cy adjusting Fisher exact test, P=0.046 after Bonferroni correc-
tion) and the location (one lobe and both lobe) (P=0.004 in 
genotype frequency adjusting Fisher exact test, P=0.008 after 
Bonferroni correction; P=0.006 in allele frequency adjusting 
Fisher exact test, P=0.012 after Bonferroni correction).
  In recent times, several genetic studies have reported relation-
ship between PTC and candidate genes, such as WD repeat do-
main 3 (WDR3) (25), vascular endothelial growth factor A 
(VEGFA) (26), RAD52 homolog (S. cerevisiae) (RAD52) (27), 
protein tyrosine phosphatase, receptor type, J (PTPRJ) (28), pu-
rinergic receptor P2X, ligand-gated ion channel, 7 (P2X7) (29), 
interleukin 6 (interferon, beta 2; IL6) (30), IL10 (31) and IL11 
(32). 
  There is one study that investigated for the relationship be-
tween BCL2 SNPs and thyroid cancer. Ruiz-Llorente et al. (22) 
reported that a BCL2 SNP was associated with the development 
of sporadic medullary thyroid cancer (MTC) in the Spanish 
population. The genotype distribution of the rs1801018 SNP 
was different between MTC patients and controls (P=0.002 in 
codominant model, P=0.56 after Bonferroni correction). Their 
study did not show the promoter SNP (rs2279115, -938A/C) of 
BCL2 and the clinicopathologic characteristics, such as size, 
number, location, extrathyroidal invasion, and lymph node me-
tastasis of cancers. Although we use PTC instead of MTC, the 
results show similar patterns. For the exact correlation between 
BCL2 and thyroid cancer, other studies with larger sample size 
and based on different populations will be needed. In this study, 
associations between synonymous SNP (rs1801018, Thr7Thr) 
and the clinicopathologic features of PTC were found. The 
rs1801018 was associated with susceptibility to the number of 
PTC. The A/G genotype and G allele frequencies of rs1801018 
in PTC patients with multifocality (A/G genotype, 26.7%; G al-
lele, 13.3%) were about four-fold higher than those in PTC pa-
tients with unifocality (A/G genotype, 6.8%; G allele, 3.4%). 
The rs1801018 was also associated with the location of PTC. 
The A/G genotype and G allele frequencies of rs1801018 in 
PTC patients with both lobes (A/G genotype, 30.8%; G allele, 
15.4%) were increased by about five-fold, compared to PTC pa-
tients with one lobe involvement (A/G genotype, 6.3%; G al-
lele, 3.2%). Therefore, we propose that rs1801018 could be a 
useful marker for the number and location of PTC, and the G 
allele of rs1801018 may be a risk factor for multifocality or bi-
laterality of PTC. Although PTC has a good prognosis following 
appropriate treatment, the multifocality and bilaterality of PTC 
are indications for complete thyroidectomy and post-operative 
radioactive iodine ablation. 
  To determine whether the promoter SNP affects transcription 
factors, we used the online program AliBaba 2.1 (http://www.
gene-regulation.com/pub/programs/alibaba2). At the sites of the 
rs2279115 SNP in BCL2, the A-containing sequences can bind 
with Id2 and SP1 transcription factors, and the G-containing se-
quences bind only with SP1. Assuming transcription factor bind-
ing varies with promoter SNPs, this promoter SNP may influence 
gene and protein expressions of BCL2. This study has several 
limitations. The control group did not undergo thyroid ultraso-
nography to exclude potentially undetected thyroid cancers. 
Considering the incidence of thyroid cancer (0.5–10/100,000 
person), this limitation imposes low impact on this study. Small 
sample size was another limitation. To confirm our results, addi-
tional study with larger sample size should be conducted. An-
other limitation is absence of study using tumor tissue, the ge-
netic changes of BCL2 will be examined in a cell line and im-
munohistochemical study in specimen tissue to determine the 
biologic effects.
  In conclusion, our results indicate that synonymous SNP 
rs2010963 (Thr7Thr) of the BCL2 gene may be associated with 
the multifocality or bilaterality of PTC, and the G allele could 
be a risk factor for multifocality or bilaterality of PTC in Korean 
population.
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